Summary of AnaptysBio Conference Call Company Overview - **Company**: AnaptysBio - **Key Product**: Jemperli, a drug for endometrial cancer, partnered with GSK - **Upcoming Spin-off**: Separation of biopharma assets into a new entity named First Tracks Bio, ticker "Tracks" [2][16] Key Points on Jemperli - **Sales Performance**: Jemperli has a current run rate of $1.4 billion, with GSK projecting peak sales exceeding $2.7 billion, indicating a growth rate in the mid-teens percentage quarter-over-quarter [3][4] - **Royalty Structure**: AnaptysBio holds an 8% royalty on sales up to $1 billion, escalating to 25% for sales above $2.5 billion. Expected royalties for this year are around $200 million, with projections of $400 million at peak sales by 2029 [4][5] - **Litigation with GSK**: Ongoing litigation regarding contractual breaches related to GSK's development of Jemperli in combination with other drugs. AnaptysBio claims this violates exclusivity agreements [8][9] - **Legal Proceedings**: A bench trial is scheduled for July 14, with a hearing on a motion to dismiss GSK's counterclaim expected within 60 days [12][10] Spin-off Details - **Separation Timeline**: The spin-off is expected to be effective by the end of April, independent of the litigation outcomes [16][17] - **Financial Structure**: The spin-off will include cash and specific liabilities, with the parent company remaining focused on royalty income [16][18] ANB033 Development - **Target Indication**: ANB033 is in phase 1 development for celiac disease, with a significant market opportunity as there are currently no approved therapies for patients not controlled on a gluten-free diet [19][20] - **Mechanism of Action**: ANB033 is a CD122 antagonist that blocks IL-15 and IL-2 signaling, targeting inflammatory pathways in celiac disease [20][21] - **Market Size**: Approximately 250,000 patients in the U.S. are not adequately managed on gluten-free diets, representing a substantial market for ANB033 [25][28] Eosinophilic Esophagitis (EoE) - **Market Potential**: EoE affects around 175,000 patients in the U.S. who are biologic-eligible. Current treatments like Dupixent show efficacy in only 60%-70% of patients [45][46] - **Differentiation**: ANB033 aims to target both CD8 and CD4 cells, potentially offering a more comprehensive treatment compared to existing therapies [43][44] Future Development Plans - **Additional Indications**: AnaptysBio plans to explore further indications beyond celiac disease and EoE, with aspirations to enter phase 2B trials for multiple diseases by 2028 [49][51] - **Funding Strategy**: The company is focused on maintaining sufficient capital to support its biopharma business through at least the end of 2027 [50][52] Financial Outlook - **Cash Flow Projections**: The parent company is expected to be cash flow positive by mid-2027, with minimal operational expenses [5][4] - **Shareholder Value**: AnaptysBio aims to create value for shareholders through potential share repurchases and leveraging its royalty income [52][54]

Company Overview - AnaptysBio is in the process of spinning off its biopharma operations into a new company called First Tracks Bio, expected to be established in one to two months [2] - AnaptysBio has over 20 years of experience in developing antibodies, with two successful programs: Jemperli (dostarlimab), an oncology drug sold by GSK, and imsidolimab, which has a PDUFA date at the end of the year and is expected to be sold by Vanda [2][3] Current Programs - The company is retaining its name AnaptysBio for the royalty-based financial entity that will hold the two successful programs [3] - In the biopharma segment, AnaptysBio is developing AMB033, a CD122 antagonist for celiac disease and EoE in Phase Ib, and rosnilimab, a PD-1 depleter with positive Phase IIb data in arthritis [3] - AnaptysBio is planning to meet with the FDA this quarter to discuss the next steps for the rosnilimab program and is seeking strategic or financial capital to advance its initiatives [4]

AnaptysBio FY Conference Summary Company Overview - AnaptysBio is a biotechnology company with over 20 years of experience in developing antibodies, currently preparing to spin off its biopharma operations into a new entity called First Tracks Biotherapeutics [6][4] - The company has two successful programs: - Jemperli (dostarlimab), an oncology drug sold by GSK, which generated approximately $1.4 billion in revenue last year, translating to about $100 million in royalties for AnaptysBio [19][111] - Imsidolimab, which is expected to have a Phase 2 readout by the end of the year and is anticipated to be sold by Vanda [6][6] Financial Structure Post-Separation - AnaptysBio will retain a royalty-based financial structure with high EBIT margins in the mid-high 90% range, minimal operational expenses (less than $10 million annually), and fewer than 10 full-time employees [17][25] - The company expects to be cash flow positive by mid-2027, with a projected need for $100 million to fund the biopharma business into Q3 of 2027 and $200 million to fully fund it into the latter half of 2028 [32][34] Pipeline and Product Development ANB033 (CD122 Antagonist) - ANB033 is being developed for Celiac Disease and Eosinophilic Esophagitis (EoE), with a Phase 1b trial design that includes two cohorts: one undergoing a gluten challenge and another with patients showing signs of mucosal injury [38][50] - The trial aims to measure histological outcomes and symptom severity, with results expected in Q4 of this year [68][66] - The company believes it has a competitive edge due to its dual-targeting mechanism, which blocks both IL-2 and IL-15 pathways [70][78] EoE Program - The EoE trial is set to initiate with a 50-patient cohort, focusing on histological outcomes and patient-reported outcomes (PRO) [84][85] - The approach targets TH2 CD4 cells and ILC2s, differentiating it from Dupixent, the only approved therapeutic for EoE, which targets eosinophils directly [90][91] Competitive Landscape - AnaptysBio faces competition from other companies targeting the IL-15/CD122 pathway, including Teva and Novartis, but believes its dual-targeting approach provides a distinct advantage [71][75] - The company is optimistic about its potential to address a broader patient population, including those who are Dupixent-experienced and Dupixent-naive [95][96] Royalty Business and Future Outlook - The royalty business is anchored by Jemperli, which is projected to grow significantly, with GSK aiming for peak sales of $2.7 billion by 2029, resulting in close to $400 million in royalties for AnaptysBio [111][113] - The company is focused on protecting and maximizing the value from existing royalties rather than expanding into new drugs [111][112] - AnaptysBio anticipates exiting the year with two commercial-stage royalties, including imsidolimab, which is awaiting approval for generalized pustular psoriasis [122][122] Conclusion - AnaptysBio is strategically positioning itself for growth through the separation of its biopharma operations, a strong pipeline of innovative therapies, and a robust royalty business model that leverages existing successful products [6][4][111]

AnaptysBio FY Conference Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Event**: FY Conference on March 04, 2026 - **Key Speakers**: Daniel Faga, President and CEO Key Points Business Separation - AnaptysBio is separating its biopharma operations from its royalty business, with the separation expected to be completed in the next couple of months [2][4] - The royalty business is projected to generate substantial revenue, particularly from the drug Jemperli, which is on a trajectory of over $1.4 billion in run rate revenue for GSK [4][21] - The separation aims to unlock value for shareholders by allowing investors to focus on either the high-margin royalty business or the biopharma operations [6][10] Financial Projections - Jemperli is expected to generate approximately $200 million in royalties for AnaptysBio this year [4] - The biopharma business will require funding, with estimates suggesting that $100 million would support operations into the second half of 2027, while $200 million would extend this into 2028 [19] - The royalty business is expected to be cash flow positive by the second half of 2027 [18] Jemperli Performance - Jemperli's revenue growth is driven by its competitive edge over Keytruda, particularly in endometrial cancer, with GSK's revenue growth in the mid-teens quarter-over-quarter [21][22] - GSK is expected to receive pivotal trial data for Jemperli in rectal cancer, which could further enhance its market position [22][24] Litigation with GSK - AnaptysBio is involved in litigation with GSK regarding Jemperli, focusing on GSK's alleged breaches of exclusivity obligations and commercial return efforts [28][29] - The litigation is not expected to impact the timing of the business separation [28] Biopharma Operations - The biopharma segment will focus on drugs like ANB033 (a CD122 antagonist) and ANB101 (a BDCA-2 modulator) [5][36] - ANB033 is being developed for celiac disease, targeting inflammation rather than just the antigen, which is a novel approach in this space [37][38] - The company is also exploring the use of ANB033 for Eosinophilic Esophagitis (EoE), leveraging its mechanism of action to target inflammatory pathways [55] Clinical Trials and Opportunities - ANB033 is undergoing trials with results expected by Q4 2026, focusing on mucosal healing in celiac disease patients [39][45] - The target population for ANB033 includes approximately 250,000 patients in the U.S. who are non-responsive to a gluten-free diet [51] - The company is also considering expanding into other indications, such as vitiligo, depending on the success of ongoing trials [59] BDCA-2 Modulator Development - The BDCA-2 modulator is in a Phase 1A trial, with differentiation from competitors being a key focus [60] - The company aims to demonstrate a longer half-life and a better profile compared to existing treatments [61] Conclusion AnaptysBio is strategically positioning itself for growth through the separation of its biopharma and royalty businesses, with a strong focus on innovative drug development and addressing unmet medical needs in celiac disease and EoE. The company is optimistic about its financial outlook and the potential for significant market opportunities in the coming years.

Core Insights - AnaptysBio is planning to separate its operations into two publicly traded companies: a royalty company focused on Jemperli and imsidolimab royalties, and a biopharma company concentrating on pipeline development [4][6]. Royalty Business - Jemperli is identified as the primary value driver, projected to exceed $1.4 billion in run-rate revenue by the end of 2025, with a growth rate in the mid-teens quarter over quarter [1][6]. - The royalty business operates with fewer than 10 employees and less than $10 million in annualized operating expenses, indicating high EBIT margins in the high 90% range [2]. Separation Plans - The company is on track to complete the separation of its biopharma operations from its royalty business within the next couple of months, retaining royalty rights on Jemperli and future royalties from imsidolimab [3][4]. - The final cash split between the two entities is still under evaluation [11]. Financial Overview - AnaptysBio started the year with approximately $310 million in cash, with the royalty business needing around $20 million for runway, while the biopharma side would require about $100 million to fund ANB033 through phase 2 trials [5][9][10]. - The royalty company is expected to be GAAP positive from the outset and cash-flow positive in the latter half of 2027 [9]. Pipeline Development - The biopharma company will focus on ANB033, ANB101, and rosnilimab, with ANB033 targeting celiac disease and eosinophilic esophagitis [15][18][19]. - Rosnilimab has shown promising results in rheumatoid arthritis, with plans to meet the FDA to discuss phase 3 parameters [14]. Legal Matters - An ongoing dispute with GSK regarding contractual obligations in combination development is noted, but the separation is stated to be unrelated to this litigation [13]. Market Opportunity - There are over 2 million people in the U.S. with celiac disease, with a significant portion being non-responsive to a gluten-free diet, representing a target population for ANB033 [17].

AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to a loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +78.53%. A quarter ago, it was expected that this company would post a loss of $1.06 per share when it actually produced earnings of $0.52, delivering a surprise of +149.06%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ______________________________________ ANAPTYSBIO, INC. (Ex ...

Core Insights - AnaptysBio, Inc. is planning to spin off its biopharma operations into a new public company named First Tracks Biotherapeutics in Q2 2026, aiming to enhance value for investors by separating its biopharma assets from its royalty portfolio [2][5][6] - The company reported strong financial results for Q4 2025, with collaboration revenue significantly increasing due to the performance of Jemperli, which achieved $343 million in sales for the quarter [4][12] Spin-off Details - The spin-off is expected to occur as early as late-April 2026, creating two independent publicly traded companies with distinct business focuses [5][6] - First Tracks Biotherapeutics will concentrate on developing innovative immunology therapeutics, including ANB033, which is currently in Phase 1b trials for celiac disease and eosinophilic esophagitis [5][6][11] - AnaptysBio will retain its name and manage financial collaborations, including those with GSK and Vanda Pharmaceuticals [6] Financial Performance - AnaptysBio reported cash and investments of approximately $311 million as of December 31, 2025, down from $420.8 million a year earlier, primarily due to operating expenses and share repurchases [12][13] - Collaboration revenue for Q4 2025 was $108.2 million, a significant increase from $43.1 million in Q4 2024, driven by Jemperli's sales milestones [12][21] - The company achieved a net income of $49.6 million for Q4 2025, compared to a net loss of $21.8 million in the same period of 2024 [12][21] Product Pipeline - ANB033 is currently undergoing a Phase 1b trial for celiac disease and eosinophilic esophagitis, with top-line data expected in Q4 2026 and 2027, respectively [11][12] - Rosnilimab, another product in the pipeline, has completed a Phase 2b trial for rheumatoid arthritis, with further updates anticipated in Q2 2026 [9][14] - The company has also filed a BLA for imsidolimab, targeting generalized pustular psoriasis, with an FDA action date set for December 12, 2026 [7][14]

AnaptysBio Conference Call Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Date**: February 12, 2026 Key Points Separation of Royalty Pharma and Biopharma - The separation of the royalty company and the biopharma business is a top priority, targeted for completion in Q2 2026, though it may extend beyond April 1 [2][4] - The royalty company will focus on recognizing the value of commercial entities with low operational expenses, driven by the growth of Jemperli and Imsidolimab [4][5] Financial Position - AnaptysBio started the year with $310 million in cash, approximately $11 per share [7] - The company plans to allocate sufficient cash to the biopharma business to support operations through 2027, potentially extending cash reserves into 2028 [7][8] Jemperli Performance - Jemperli reported Q4 sales of $343 million, reflecting a 13% quarter-over-quarter growth [12] - It is positioned as a best-in-class PD-1 antagonist, with significant growth potential driven by multiple indications, including rectal cancer and MSI-H colon cancer [13][15] - Analysts have not fully recognized Jemperli's growth potential, with some assigning negative growth rates despite its rapid sales increase [14] ANB033 and Celiac Disease - ANB033, a CD122 antagonist, is being developed for celiac disease, targeting a market with over 2 million patients in the U.S. [21][22] - The study design includes a gluten challenge with a focus on histological outcomes and patient-reported outcomes [24][25] - Data readout is expected in Q4 2026, with enrollment having started in Q4 2025 [27][28] Eosinophilic Esophagitis (EoE) - The company is also advancing a program for EoE, with a focus on reducing eosinophils and improving patient-reported outcomes [52] - The market for EoE is significant, with dupilumab generating approximately $2 billion annually [48] Rosnilimab Development - Rosnilimab has shown promising results in rheumatoid arthritis, with plans to advance it through partnerships rather than using balance sheet cash [55][56] - An update on the phase 3 advancement is expected in the first half of 2026 [54] BDCA2 Modulator (ANB101) - ANB101 is in phase 1 development, with potential applications in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) [60] - The company is monitoring Biogen's trials for insights on advancing ANB101 [61] Legal Considerations - Ongoing litigation with GSK regarding contractual issues could impact the royalty business, with potential for the drug to revert back to AnaptysBio [65][66] Conclusion - AnaptysBio is positioned for significant developments in 2026, with multiple catalysts including the separation of its businesses, Jemperli's growth, and advancements in its clinical programs [68]

Core Viewpoint - AnaptysBio plans to separate its business into two publicly traded entities, focusing on biopharma operations and a royalty portfolio, with a target separation date in Q2 2026, although this may be subject to slight delays [4][7]. Biopharma Operations - The new biopharma entity will include three clinical-stage programs: CD122 (ANB033), ANB101, and rosnilimab, and will be capitalized to reach key readouts in the CD122 program [2][5][12]. - AnaptysBio entered 2026 with approximately $310 million in cash, which could fund the biopharma operations into 2028 if allocated appropriately [5][11]. - CD122 is currently in a phase 1b trial for celiac disease, with data expected in Q4 2026, and plans to initiate a phase 1b trial for eosinophilic esophagitis imminently, with results anticipated in 2027 [13][14]. Royalty Portfolio - The royalty-focused entity will be anchored by royalties on GSK's Jemperli, which is projected to have a revenue run rate of approximately $1.5 billion, potentially reaching $1.8 billion this year if growth trends continue [6][7]. - The royalty rate for Jemperli is structured at 8% up to $1 billion in revenues, escalating to 25% at $2.5 billion [9]. - The royalty entity will also include potential economics from Vanda's imsidolimab, which is seeking accelerated approval for generalized pustular psoriasis [10]. Market Dynamics - Faga noted that GSK's Jemperli has gained market share in frontline endometrial cancer due to positive overall survival data, with European approvals lagging behind the U.S. [8]. - GSK has historically guided for peak sales of Jemperli to exceed £2 billion (approximately $2.7 billion), with potential for additional indications and combinations to contribute to revenue [8]. Strategic Considerations - The separation is framed as a dividend of the biopharma operations to existing shareholders, allowing them to retain proportional ownership in both entities post-separation [3][4]. - AnaptysBio is also addressing ongoing litigation related to Jemperli, which is described as a specific contractual matter that does not impact the separation process [10].